WALTHAM, Mass--(BUSINESS WIRE)--
NeuroMetrix, Inc. (Nasdaq: NURO), an innovative health care company that
develops wearable medical technology and point-of-care tests to help
patients and physicians manage chronic pain, nerve diseases, and sleep
disorders, has been featured in several media outlets and in patient
interviews.
The Company operates in two primary markets - wearable medical
technology and point-of-care tests. The Company's SENSUS™ device is a
wearable transcutaneous electrical nerve stimulator indicated for
management of chronic pain, and is the only such device cleared by the
FDA for use during sleep. It is lightweight and can be worn during the
day while remaining active, and at night while sleeping. SENSUS is
beneficial in treating various forms of chronic pain, particularly
neuropathic pain such as painful diabetic neuropathy, which affects
about one quarter of people with diabetes. The Company's point-of-care
neuropathy test, DPNCheck®, addresses an unmet medical need
for accurate and cost-effective screening, diagnosing and monitoring of
peripheral neuropathies such as diabetic peripheral neuropathy. DPNCheck
has found growing acceptance among Medicare Advantage plans where it is
used in the clinically and financially important risk adjustment process.
Shai Gozani, M.D., Ph.D., President and Chief Executive Officer of
NeuroMetrix participated in a live interview and Q&A session with TuDiabetes.org,
a diabetic community and a program of the Diabetes
Hands Foundation. The discussion covered a wide range of
diabetes and neuropathy topics and included discussion of SENSUS and
DPNCheck. To listen to the interview, please visit the following link: http://youtu.be/JPJ7BSA66Hk
In an article by Dr. Vincent R. Forte, Interventional Pain Management
Specialist at Louisiana Pain Care, on the topic of "Managing Painful
Diabetic Neuropathy", Dr. Forte described SENSUS as a simple, convenient
therapy that has provided encouraging results in clinical settings. He
emphasized the "on-demand" aspect of SENSUS and its effectiveness during
sleep. The article was published in the March poster of Physicians
Weekly which is distributed to 1,500 U.S. hospitals and
clinics. To see the poster, please visit the following link: http://www.physiciansweekly.com/diabetic-neuropathy-pain-management/
DiaTribe which covers
research and product news for people with diabetes published "Diabetic
Neuropathy - Knowledge is Power" by Alasdair Wilkins. The article
describes diabetic neuropathy, the warning signs, prevention, and
treatment options. It mentions medications to help manage the pain that
can accompany neuropathy and it covers the SENSUS Pain Management
System. To read the article, please visit the following link: http://www.diatribe.org/issues/61/learning-curve/2?utm_source=diaTribe&utm_campaign=8dc6a2ec8b-diaTribe_Issue_59&utm_medium=email&utm_term=0_75cdadd67f-8dc6a2ec8b-410724717
The spring edition of Better Homes and
Gardens - Diabetes Edition includes an article "Stand Up
To Leg Pain" which discusses diabetic neuropathy and highlights SENSUS
as an FDA approved TENS device that can be worn under clothes during the
day and at night to address neuropathic pain. To read the article,
please visit the following link: http://www.sensusrx.com/about-neurometrix/news-and-events/better_homes_&_gardens_-_diabetic_living_spring_2014_final.pdf
Recent interviews with patients using SENSUS have highlighted its
benefits. Patients emphasize its role in allowing them to return to a
more active lifestyle. A recurring theme is the ability to improve sleep
duration and quality, and the attendant benefits in quality of life.
Convenience of use is often mentioned. To hear these and other patient
commentary on SENSUS, please visit the NeuroMetrix website at the
following link: http://www.sensusrx.com/learn-about-sensus/user-experiences.html
About NeuroMetrix
NeuroMetrix is an innovative health-care company that develops wearable
medical technology and point-of-care tests that help patients and
physicians better manage chronic pain, nerve diseases, and sleep
disorders. The Company has a major focus on diabetic neuropathies, which
affect over 50% of people with diabetes. If left untreated, diabetic
neuropathies trigger foot ulcers that may require amputation and cause
disabling chronic pain. The annual cost of diabetic neuropathies has
been estimated at $14 billion in the United States. The Company markets
the SENSUS device for treating chronic pain, focusing on physicians
managing patients with neuropathic pain such as painful diabetic
neuropathy. The Company also markets DPNCheck, which is a rapid,
accurate, and quantitative point-of-care test for peripheral
neuropathies such as diabetic neuropathy. This product is used to detect
neuropathies at an early stage and to guide treatment. For more
information, please visit http://www.NeuroMetrix.com.
NeuroMetrix, Inc.
Thomas T. Higgins, 781-314-2761
Chief
Financial Officer
neurometrix.ir@neurometrix.com
Source: NeuroMetrix
News Provided by Acquire Media
